



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 30.05.2025

To
The Department of Corporate Services,
The BSE Limited
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 30th May, 2025

Pursuant to provision of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its Board Meeting held on Friday, 30th May, 2025, inter-alia, considered the following matters:

1. Considered and approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Considered and approved the Directors' Report with the Annexure, Corporate Governance report, Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company.
3. Based on the recommendations of Audit Committee, Board of Directors approved the Appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretary [peer review company secretary], as Secretarial Auditor of the Company for a term of Five consecutive years, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read along with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith as **Annexure.**

4. Considered and approved the re-appointment of Internal Auditors of the Company for the year 2025-26.

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

5. Taken on record the Disclosure of Interest of Directors of the Company for the year 2025-26.

A declaration under SEBI Circular CIR/CFD/CMD/56/2016 Dated 27th May, 2016, in respect of Statutory Auditors issued Audit Report with unmodified opinion for financial results for the financial year ended 31st March, 2025 is enclosed herewith.

The meeting was commenced at 05:00 p.m. and concluded at 05:45 p.m.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Independent Auditor's Report on the Quarterly and Annual Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Ishita Drugs & Industries Ltd.

Opinion

We have audited the accompanying Statement of Standalone Financial Results of ISHITA DRUGS AND INDUSTRIES LTD("the Company"), which includes joint operations for the quarter and year ended 31st March 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b) gives a true and fair view in conformity with applicable Indian accounting standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the Company for the year ended March 31, 2025.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results

section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Standalone Financial Results.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Standalone Financial Statements. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with Indian accounting standards prescribed under section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate



accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The statement includes the results for the quarter ended 31st March 2025 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures up to the nine months of the current financial year which were subject to limited review by us.

Date: 30/05/2025

Place: Ahmedabad

For, and on Behalf of
JAYMIN SHAH AND ASSOCIATES



Mayank Sancheti
(Partner)

MNo.: 170863

FRN: 129406W

UDIN: 25170863BMLNGT3304

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Audited Financial Results for the Quarter and Year Ended March 31, 2025

Amount in Lakhs except Per Share data

Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended in the previous Year	Year to date figures for current year ended	Year to date figures for previous year ended
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
	Audited	Un-audited	Audited	Audited	Audited
1 INCOME					
Revenue from Operations	456.36	413.18	449.61	1499.73	1518.76
Other Income	15.99	6.70	10.39	33.57	28.02
Total Income	472.35	419.88	459.99	1533.30	1546.78
2 EXPENSES					
(a) Cost of Material Consumed	315.06	292.28	362.80	1010.94	1137.46
(b) Purchase of Stock-In-Trade	23.79	5.62	0.00	33.71	6.40
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	17.99	(17.51)	(11.23)	23.56	(14.51)
(d) Employee Benefit Expense	31.86	35.73	34.10	134.43	133.89
(e) Finance Cost	4.27	1.83	1.57	7.22	8.98
(f) Depreciation, Depletion and Amortisation Expense	2.60	2.79	1.17	10.98	11.17
(g) Other Expense	38.51	67.35	34.60	196.93	164.67
Total Other Expenses	38.51	67.35	34.60	196.93	164.67
Total Expenses	434.09	388.09	423.01	1417.78	1448.06
3 Total Profit before Exceptional Items and Tax	38.25	31.79	36.98	115.51	98.73
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	38.25	31.79	36.98	115.51	98.73
6 Tax Expense					
7 Current Tax	10.25	8.00	8.93	29.50	24.00
8 Deferred Tax	(0.79)	0.00	(0.12)	(0.79)	(0.12)
9 Total Tax Expenses	9.46	8.00	8.80	28.71	23.88
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	28.80	23.79	28.18	86.81	74.85
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
14 Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
16 Total Profit / (Loss) for the period	28.80	23.79	28.18	86.81	74.85



Jaydev



17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	28.80	23.79	28.18	86.81	74.85
19	Total profit or loss attributable to					
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to					
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital					
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities					
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share					
(i)	Earnings Per Share for continuing operations					
	Basic Earnings / (Loss) per share from continuing operations	0.96	0.80	0.94	2.90	2.50
	Diluted Earnings / (Loss) per share from continuing operations	0.96	0.80	0.94	2.90	2.50
(ii)	Earnings Per Share for discontinued operations					
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share					
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.96	0.80	0.94	2.90	2.50
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.96	0.80	0.94	2.90	2.50
26	Debt Equity Ratio	0.00	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00

Dayanidhi



NOTES	
1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on May 30th, 2025.	
2. Results for the quarter and year ended 31st March, 2025, are in compliance with Indian Accounting Standards ('IndAS') notified by the Ministry of Corporate Affairs.	
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment. Hence no segment wise figures are published.	
4. The figures for the quarter ended 31st March, 2025, are balancing figures between audited figures in respect of full financial year ended 31st March, 2025, and the published year to date figures upto the third quarter ended 31st December, 2024, which have been regrouped / rearranged wherever necessary.	
5. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com .	
<div style="display: flex; justify-content: space-between; align-items: center;"> <div>  </div> <div> For, ISHITA DRUGS AND INDUSTRIES LIMITED  JAGDISH AGRAWAL MANAGING DIRECTOR DIN: 01031687 </div> </div>	
Place	Ahmedabad
Date	30-May-25

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in Lakhs

	Particulars	Year Ended	Previous Year Ended
		Audited	Audited
		31/03/2025	31/03/2024
		Rs. In Lakhs	Rs. In Lakhs
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	87.90	80.46
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	87.90	80.46
	Non-current investments	35.48	27.15
	Trade receivables, non-current		
	Loans, non-current		
	Other non-current financial assets	7.86	7.56
	Total Non-current financial assets	43.34	34.71
	Deferred tax assets (net)		
	Other non-current assets		
	Total Non-current Assets	131.24	115.17
2	Current assets		
	Inventories	446.49	106.42
	Current financial assets		
	Current investments	351.51	306.51
	Trade receivables, current	189.82	69.90
	Cash and cash equivalents	56.84	182.53
	Bank balance other than cash and cash equivalents	426.54	298.45
	Loans, current	23.91	0.12
	Other current financial assets	3.24	1.77
	Total current financial assets	1051.86	859.28
	Current tax assets (net)		
	Other current assets		
	Total Current Assets	1498.35	965.70
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	TOTAL ASSETS	1629.58	1080.87

[Signature]



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	299.03	299.03
	Other equity	779.93	693.12
	Total Equity attributable to owners of Parent	1078.96	992.15
	Non controlling interest		
	Total Equity	1078.96	992.15
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	8.94	0.00
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	8.94	0.00
	Provisions, non-current		
	Deferred tax liabilities (net)	1.19	1.99
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	10.14	1.99
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	381.35	0.00
	Trade payables, current	94.94	45.82
	Other current financial liabilities	0.00	0.00
	Total current financial liabilities	476.29	45.82
	Other current liabilities	25.16	14.95
	Provisions, current	17.82	12.32
	Current tax liabilities (Net)	21.21	13.63
	Deferred government grants, Current	0.00	
	Total current liabilities	540.48	86.73
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities	550.62	88.71
	Total Equity and Liabilities	1629.58	1080.87

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 30-May-25

DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

AUDITED CASH FLOW STATEMENT

Amount in Lakhs

Sr. No.	Particulars	Audited Year Ended 31/03/2025 Rs. In Lakhs	Audited Year Ended 31/03/2024 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	115.51	98.73
	Add : Depreciation	10.98	11.17
	Interest & Other financial charges	7.22	8.98
	Loss on sale of fixed assets	0.00	0.00
	Less : Interest received	28.46	18.06
	Dividend received	0.04	0.09
	Income from Investments	5.08	9.87
	Prior Period Items	0.00	0.00
	Deferred Tax Assets	0.00	0.00
	Profit on sale of fixed assets	0.00	0.00
	Operating profit before change in working capital	100.14	90.85
	Add : Trade Debtors	(119.92)	110.13
	Decrease/(Increase) in Inventory	(340.07)	53.41
	Decrease/(Increase) in Loans and advances	(25.56)	20.22
	Less : Fringe Benefit Tax	0.00	0.00
	Less : Provision for Deferred Tax	0.00	0.00
	Less : Provision for Taxation	29.50	24.00
	Less : Prior Period items	0.00	0.00
	Decrease/(Increase) Share Term Provision	0.00	5.44
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	(51.20)	33.09
	Net cash generated from operating activities (A)	(363.71)	212.08
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	(53.33)	5.74
	Dividend received	0.04	0.09
	Income from Investments	5.08	9.87
	Profit on sale of fixed assets	0.00	0.00
	Less : Capital work in progress	0.00	0.00
	Loss on sale of fixed assets	0.00	0.00
	Less : Investment in fixed assets	18.42	2.68
	Net cash generated from investing activities (B)	(66.63)	13.03
(C)	Cash flow from financial activities :		
	Add : Gains of settlement of debts	0.00	0.00
	Add : Interest received	28.46	18.06
	Borrowings	411.51	(96.04)
	Less : Repayment of borrowings	0.00	0.00
	Less : Interest & Other financial charges	7.22	8.98
	Net cash generated from financial activities (C)	432.74	(86.95)
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	2.40	138.15
	Opening balance of Cash and cash equivalents	480.98	342.83
	Closing balance of Cash and cash equivalents	483.38	480.98
	Net Increase/(decrease) in Cash & Cash Equivalents	2.40	138.15

Note : Figures in bracket indicate negative value

Correctly extracted from Audited accounts of the Company



For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal

JAGDISH AGRAWAL
MANAGING DIRECTOR

DIN: 01031687

Place **Ahmedabad**

Date **30-May-25**



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 30.05.2025

To,
The Department of Corporate Services,
The BSE Limited
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 w.r.t. Audit Report with unmodified opinion

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, have issued an Audit Report with unmodified opinion on the Standalone Annual Financial Results of the Company for the year ended 31st March, 2025.

Kindly take the above on your records.

Thanking You

For Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Annexure - I

Information as required under Regulation 30 - of SEBI

(Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	Reasons for Change viz. appointment, resignation , removal , otherwise;	Appointment of M/s. Meenu Maheshwari & Associates, peer reviewed Company Secretary, as a Secretarial Auditor of the Company.
2.	Date of appointment / cessation (as applicable) & terms of appointment	The Board at its meeting held on 30 th May, 2025, approved the appointment of M/s. Meenu Maheshwari & Associates, as Secretarial Auditor, for a term of 5 (Five) consecutive years, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
3.	Brief Profile	<p>Mrs. Meenu Maheshwari is a peer reviewed, qualified Company Secretary with over 15 years of experience in providing corporate consultancy services to listed, unlisted, private companies including LLPs.</p> <p>She provides a wide range of services including due diligence audit, secretarial audit, issuance of certificates related to MCA and ROC compliances and other legal compliances of listed and unlisted companies.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359